Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
ANZCA have also established a dedicated webpage for GLP-1 receptor agonists - clinical practice recommendations which includes links to: The guidance document Clinical Practice Recommendations regarding patients taking GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists prior to anaesthesia or sedation for surgical and endoscopic procedures
It works by increasing insulin production and lowers glucagon secretion as well as targets areas in the brain that regulate appetite and food intake
Debilitating exhaustion is not an expected or acceptable side effect and requires thorough evaluation
Retatrutide, a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, is currently in late-stage clinical trials and showing even greater weight loss results than its predecessors
